Edition:
United States

Sellas Life Sciences Group Inc (SLS.OQ)

SLS.OQ on NASDAQ Stock Exchange Capital Market

4.93USD
19 Jun 2018
Change (% chg)

$0.04 (+0.82%)
Prev Close
$4.89
Open
$4.90
Day's High
$4.99
Day's Low
$4.77
Volume
8,100
Avg. Vol
94,935
52-wk High
$19.32
52-wk Low
$3.43

Chart for

About

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunothera... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $32.94
Shares Outstanding(Mil.): 6.66
Dividend: --
Yield (%): --

Financials

  SLS.OQ Industry Sector
P/E (TTM): -- 29.92 34.14
EPS (TTM): -13.60 -- --
ROI: -140.99 13.64 13.17
ROE: -248.18 15.43 15.14

BRIEF-Sellas Life Sciences Files For Offering Of Up To $30 Mln

* SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO $30 MILLION - SEC FILING Source text: (https://bit.ly/2klt2uI) Further company coverage:

May 23 2018

BRIEF-Sellas Life Sciences Group Files Preliminary Prospectus Related To Offering Of 3.2 Mln Shares Of Common Stock

* SELLAS LIFE SCIENCES GROUP FILES PRELIMINARY PROSPECTUS RELATED TO OFFERING OF 3.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS -SEC FILING Source: (https://bit.ly/2I5iC0q) Further company coverage:

May 10 2018

BRIEF-Sellas Life Sciences Receives FDA Orphan Drug Designation For Galinpepimut-S For Treatment Of Multiple Myeloma

* SELLAS LIFE SCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR GALINPEPIMUT-S (GPS) FOR TREATMENT OF MULTIPLE MYELOMA (MM) Source text for Eikon: Further company coverage:

May 09 2018

BRIEF-Sellas Life Sciences Ceases Gregory Torre's Employment As Chief Regulatory Officer

* SELLAS LIFE SCIENCES GROUP- ON APRIL 19, CO AND GREGORY TORRE, AGREED THAT HIS EMPLOYMENT AS CHIEF REGULATORY OFFICER WOULD CEASE - SEC FILING

Apr 24 2018

BRIEF-Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer

* SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER

Apr 20 2018

BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin

* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS

Apr 02 2018

BRIEF-Sellas Life Sciences Announces $10.7 Mln Private Placement

* SELLAS LIFE SCIENCES ANNOUNCES $10,700,000 PRIVATE PLACEMENT

Mar 07 2018

Competitors

Earnings vs. Estimates